MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 137 filers reported holding MERSANA THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $298,000 | -34.1% | 47,980 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $452,000 | -9.6% | 47,980 | +30.2% | 0.00% | -20.0% |
| Q2 2021 | $500,000 | -16.1% | 36,839 | 0.0% | 0.01% | -16.7% |
| Q1 2021 | $596,000 | -39.2% | 36,839 | 0.0% | 0.01% | -40.0% |
| Q4 2020 | $980,000 | +42.9% | 36,839 | 0.0% | 0.01% | +25.0% |
| Q3 2020 | $686,000 | -2.0% | 36,839 | +23.2% | 0.01% | 0.0% |
| Q2 2020 | $700,000 | – | 29,900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 1,191,271 | $6,980,848 | 6.79% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $50,769 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 950,000 | $5,567,000 | 3.43% |
| Sarissa Capital Management LP | 3,997,010 | $23,422,479 | 2.79% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $5,299,010 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,140,182 | $6,681,467 | 1.91% |
| Orbimed Advisors | 9,011,437 | $52,807,021 | 1.01% |
| Opaleye Management Inc. | 460,000 | $2,695,600 | 0.94% |
| Artal Group S.A. | 2,200,000 | $12,892 | 0.72% |
| DAFNA Capital Management LLC | 413,463 | $2,422,893 | 0.68% |